The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV).
excreta disposal in emergencies
This study examines the gendered impacts of the Ebola virus disease (EVD) in Liberia in the largest outbreak of EVD ever recorded. The findings are based on an extensive two-week desk study and one-week participatory field study conducted in January 2015 in the cities of Monrovia and Buchanan in Lib...eria
more
The flip book is for pre-deployment trainings for Ebola response, and is based on frequently asked questions about Ebola virus disease (EVD):
What is Ebola virus disease?
How do people become infected with EVD?
Why WHO is focusing on safe and dignified burials of people who have died ...from Ebola?
Who is most at risk?
What are the symptoms of Ebola infection?
What treatment is available for Ebola?
more
Conflict and Health 2015, 9:8 doi:10.1186/s13031-015-0035-8
Antimicrobial Resistance Surveillance and Research Network | This document contains detail procedures on sample collection, transport, isolation, identification of fungi for the diagnosis of invasive fungal infections and antifungal susceptibility testing of yeast
Les périodes périnatale et néonatale constituent des moments critiques dans la vie des mères et des nouveau-nés. En effet, pendant ces périodes, des complications obstétricales, foetales et néonatales surviennent entrainant des mort-nés, des décès néonatals et des possibilités d’incap...acités si l’enfant survit. Les présentes directives nationales de santé des nouveau-nés, définies comme des lignes de conduite données par l’Autorité, en l’occurrence le Ministre de la Santé, visent à prévenir, dépister et prendre en charge ces complications en vue de d’améliorer la qualité des soins et de réduire la morbidité et la mortalité foetales et néonatales, ainsi que les handicaps à moyen ou long terme chez l’enfant. Les directives se focalisent principalement sur la période autour de l’accouchement, les premières heures et les sept (7) premiers jours de vie de l’enfant.
Pour les rendre opérationnelles, il faudrait
more
Document is available in Arabic, Bengali, Chinese (Simplified and Traditional), Dari, Dinka, English, Farsi, Hindi, Japanese, Khmer, Korean, Nepali, Punjabi, Somali, Swahili, Tamil, Thai, Turkish, Urdu and Vietnamese. For other language versions go to http://www.schn.health.nsw.gov.au/parents-and-ca...rers/fact-sheets/jaundice-in-newborn-babies
more
Mem Inst Oswaldo Cruz , Rio de Janeiro, Vol. 110 (3): 377-386, May 2015
Journal of The Association of Physicians of India, Vol. 63 November 2015,, pp.77-96
A pocket atlas for clinical health-care professionals
The Rwandan Ministry of Health recognizes the threat that Non-Communicable Diseases (NCDs) pose to health and development in Rwanda and in 2009 articulates strategies to respond to them in the Health Sector Strategic Plan 2012 - 2018 (HSSP3). Among other things, the plan calls for a national prevale...nce survey on NCD risk factors. This report responds to that call and summarizes the findings of the first NCD risk factor survey in Rwanda conducted from November 2012 to March 2013.
more
Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE)
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more